From the Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Pediatrics, National Jewish Health, Denver, Colorado.
Allergy Asthma Proc. 2019 Mar 1;40(2):84-92. doi: 10.2500/aap.2019.40.4202.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic predisposition, epidermal barrier disruption, and dysregulation of the immune system are some of the critical components of AD. An impaired skin barrier may be the initial step in the development of the atopic march as well as AD, which leads to further skin inflammation and allergic sensitization. Type 2 cytokines as well as interleukin 17 and interleukin 22 contribute to skin barrier dysfunction and the development of AD. New insights into the pathophysiology of AD have focused on epidermal lipid profiles, neuroimmune interactions, and microbial dysbiosis. Newer therapeutic strategies focus on improving skin barrier function and targeting polarized immune pathways found in AD. Further understanding of AD pathophysiology will allow us to achieve a more precision medicine approach to the prevention and the treatment of AD.
特应性皮炎(AD)是最常见的慢性炎症性皮肤病。遗传易感性、表皮屏障破坏和免疫系统失调是 AD 的一些关键组成部分。受损的皮肤屏障可能是特应性发生发展的初始步骤,也可能导致 AD 进一步的皮肤炎症和过敏致敏。2 型细胞因子以及白细胞介素 17 和白细胞介素 22 导致皮肤屏障功能障碍和 AD 的发生。AD 病理生理学的新见解集中在表皮脂质谱、神经免疫相互作用和微生物失调上。更新的治疗策略侧重于改善皮肤屏障功能,并针对 AD 中发现的极化免疫途径。进一步了解 AD 的病理生理学将使我们能够实现更精准的医学方法来预防和治疗 AD。